In this study, we tested the hypothesis that obesity enhances LIFR signaling in TNBC, contributing to cancer progression, and tested the therapeutic potential of LIFR inhibition using the small-molecule inhibitor EC359. This evidence concerns the gene LIFR and obesity disorder.